In today’s episode, supported by Coherus Biosciences, we had the pleasure of speaking with Tarek Mekhail, MD, MSC, FRCSI, FRCSEd, about the use of toripalimab-tpzi (Loqtorz) in patients with nasopharyngeal carcinoma. Dr Mekhail is the medical director of the Thoracic Cancer Program and the Associate Executive Director at the AdventHealth Cancer Institute in Orlando, Florida.
In our exclusive interview, Dr Mekhail discussed the rationale for combining chemotherapy with the PD-1 inhibitor toripalimab in patients with nasopharyngeal carcinoma, clinical successes with toripalimab in the first- and second-line nasopharyngeal carcinoma settings, and what the future looks like regarding immunotherapy in this disease.
OncLive® On Air